Beta Bionics Faces Class Action Over Alleged iLet Safety Failures

The complaint, filed by Bleichmar Fonti & Auld LLP under the caption Holtzman v. Beta Bionics, Inc., contends that the firm concealed significant defects in its autonomous insulin pump. While the company marketed the device as a fully automated solution for diabetes management, the lawsuit alleges that an FDA Form 483 issued in June 2025 uncovered over 18,000 unreported user complaints. These reports allegedly detailed life-threatening episodes of hypoglycemia linked to the device’s dosing algorithm, which the company reportedly failed to investigate or rectify.

The financial fallout hit investors on January 8, 2026, when the company revealed that new patient adoption rates missed analyst projections by nearly 10%. This disclosure caused the stock price to plummet 37%, wiping out $11.85 in value per share in a single day. Further pressure mounted in February 2026, following the public release of an FDA warning letter that formally cited the company for its failure to report serious malfunctions. Investors seeking to participate in the litigation as lead plaintiffs have until November 3, 2026, to file with the court.